FC
ACAD icon

FORA Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

FORA Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,746
Closed -$297K – 459
2025
Q2 		$297K Buy
+13,746
New +$256K 0.03% 404
2021
Q1 		– Sell
-8,352
Closed -$446K – 735
2020
Q4 		$446K Buy
+8,352
New +$415K 0.07% 309
2020
Q3 		– Sell
-10,893
Closed -$528K – 622
2020
Q2 		$528K Buy
10,893
+4,168
+62% +$200K 0.18% 148
2020
Q1 		$284K Buy
6,725
+4,583
+214% +$189K 0.06% 363
2019
Q4 		$92K Buy
+2,142
New +$93.2K 0.01% 764

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

FORA Capital's ACAD Position: Q3 2025 in Review

FORA Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 13,746 shares — an estimated $297K sold.

FORA Capital first reported a position in ACAD in Q4 2019 and held it in 5 quarters. The position peaked at $528K in Q2 2020. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • FORA Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • FORA Capital sold 13,746 Acadia Pharmaceuticals shares in Q3 2025, an estimated $297K.
  • FORA Capital first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • FORA Capital's Acadia Pharmaceuticals position peaked at $528K in Q2 2020.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on FORA Capital's 13F filing for Q3 2025, filed 13 Nov 2025.